EUVIMEDOpdag EUVIMED
Multizentrische Studie

An Observational, Prospective, Open-Label, Multicentre Evaluation of Aliskiren in Treated, Uncontrolled Patients

Giuliano Tocci, Gianpiero Aimo, Dario Caputo, Carmine De Matteis, Tommaso Di Napoli, Antonino Granatelli, Pietro Lentini, Armando Magagna, Alfonso A Matarrese, Davide Perona, Giuseppe Villa, Massimo Volpe and 1 more

High Blood Pressure & Cardiovascular Prevention · 2012

DOI: 10.1007/bf03262457 ↗

At a glance

Multizentrische Studie in High Blood Pressure & Cardiovascular Prevention, 2012. Written by Giuliano Tocci and 12 co-authors. Institution: IRCCS Neuromed, Pozzilli, Isernia, Italy. Cited 8 times so far (Crossref); 34 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

INTRODUCTION: The addition of the direct renin inhibitor aliskiren is demonstrated to improve blood pressure (BP) control rate and reduce progression of organ damage in treated hypertensive patients in clinical trials with a relatively short follow-up period. AIM: The objective of this study was to assess the effectiveness, safety and tolerability of aliskiren as an add-on antihypertensive therapy in high-risk, treated, hypertensive patients, who were not controlled with concomitant treatment with at least two antihypertensive drugs under 'real-life' conditions, during a planned observation and treatment period of at least 12 months in Italy. METHODS: Clinical data were derived from medical databases of treated, uncontrolled, hypertensive patients followed by specialized physicians operating in different clinical settings (hospital divisions or outpatient clinics) in Italy. Aliskiren was added to stable antihypertensive treatment, including at least two drug classes (independently of class or dosage) and unable to achieve BP control. Follow-up visits for measuring clinic BP levels and collecting data on drug safety and tolerability were planned at time intervals of 1, 6 and 12 months. At each predefined follow-up visit, aliskiren could be up-titrated from 150 to 300 mg daily if BP control was not achieved. RESULTS: From May 2009 to June 2011, a total of 1186 treated, uncontrolled, hypertensive patients (46.3% female, aged 65.2 ± 11.7 years, mean duration of hypertension 13.2 ± 9.3 years, mean clinic BP levels 156.5 ± 15.9/90.3 ± 9.5 mmHg) were enrolled. Systolic and diastolic BP levels were 141.1/82.4, 134.9/79.8 and 133.6/78.9 mmHg at 1-, 6- and 12-month follow-up visits, respectively (p < 0.0001 vs baseline for all comparisons). These effects were consistent in all predefined subgroups, including those with left ventricular hypertrophy, renal disease, diabetes mellitus, coronary artery disease or cerebrovascular disease. Reduced levels of microalbuminuria were also reported, without affecting other renal and electrolyte parameters. Overall, compliance to study medication was high (93.0%), with a very low proportion of patients experiencing adverse events leading to drug discontinuation (3.6%). CONCLUSIONS: In this observational, prospective, open-label, multicentre study, we reported the 12-month clinical effectiveness, safety and tolerability of adding aliskiren to treated, uncontrolled, hypertensive patients in a 'real-life' setting in Italy. This strategy leads to a significantly improved BP control rate and low incidence of drug-related side effects or discontinuations.

Subjects

MeSH terms (MEDLINE)

Adrenergic beta-AntagonistsAdultAge FactorsAgedAlbuminuriaAmidesAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBlood PressureCalcium Channel BlockersDiastoleDiureticsDrug Therapy, CombinationFemaleFollow-Up StudiesFumaratesHumansHypertensionItaly

Substances

Adrenergic beta-AntagonistsAmidesAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCalcium Channel BlockersDiureticsFumaratesRenin Inhibitorsaliskiren

Authors and institutions

  • IRCCS Neuromed, Pozzilli, Isernia, Italy.

Cite

APA

Tocci, G., Aimo, G., Caputo, D., De Matteis, C., Di Napoli, T., Granatelli, A., Lentini, P., Magagna, A., Matarrese, A. A., Perona, D., Villa, G., Volpe, M., & DRIVE Investigators (2012). An Observational, Prospective, Open-Label, Multicentre Evaluation of Aliskiren in Treated, Uncontrolled Patients. High Blood Pressure & Cardiovascular Prevention. https://doi.org/10.1007/bf03262457

Vancouver

Tocci G, Aimo G, Caputo D, De Matteis C, Di Napoli T, Granatelli A, et al. An Observational, Prospective, Open-Label, Multicentre Evaluation of Aliskiren in Treated, Uncontrolled Patients. High Blood Pressure & Cardiovascular Prevention. 2012. doi:10.1007/bf03262457

BibTeX
@article{Tocci2012,
  author = {Tocci, Giuliano and Aimo, Gianpiero and Caputo, Dario and De Matteis, Carmine and Di Napoli, Tommaso and Granatelli, Antonino and Lentini, Pietro and Magagna, Armando and Matarrese, Alfonso A and Perona, Davide and Villa, Giuseppe and Volpe, Massimo and DRIVE Investigators, DRIVE Investigators},
  title = {An Observational, Prospective, Open-Label, Multicentre Evaluation of Aliskiren in Treated, Uncontrolled Patients},
  journal = {High Blood Pressure & Cardiovascular Prevention},
  year = {2012},
  doi = {10.1007/bf03262457}
}
Start for free →